Althea Group Holdings Limited (ASX: AGH), an Australian cannabis company, has been navigating a turbulent market. As of August 2026, the company has implemented significant cost-cutting measures, including a 30% reduction in workforce, to preserve cash amid ongoing losses.
In its latest financial report for the half-year ended December 31, 2025, Althea reported revenue of A$12.4 million, a decrease from A$14.1 million in the prior corresponding period. The company also recorded a net loss after tax of A$6.8 million, an improvement from a loss of A$9.2 million in the previous year.
The company has been focusing on its UK operations, which have shown growth, while Australian sales have been impacted by regulatory and market challenges. Althea's CEO, Josh George, stated that the company is "committed to achieving profitability" and is exploring strategic options to strengthen its balance sheet.
Analysts note that the Australian medicinal cannabis market remains highly competitive, with pricing pressures and regulatory hurdles affecting many players. Althea's shares have been volatile, reflecting investor uncertainty about the company's path to sustainability.
